Trials / Active Not Recruiting
Active Not RecruitingNCT07142811
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Vir Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tobevibart | Tobevibart administered by subcutaneous injection |
| DRUG | Elebsiran | Elebsiran administered by subcutaneous injection |
| DRUG | Bulevirtide | Bulevirtide administered by subcutaneous injection |
Timeline
- Start date
- 2025-08-05
- Primary completion
- 2026-11-01
- Completion
- 2030-07-01
- First posted
- 2025-08-27
- Last updated
- 2026-01-16
Locations
31 sites across 11 countries: Belgium, Bulgaria, France, Germany, Moldova, Netherlands, Pakistan, Romania, Spain, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07142811. Inclusion in this directory is not an endorsement.